AbbVie Ends Work on Drug From $5.8 Billion Deal After Failures
This article is for subscribers only.
AbbVie Inc. said it would stop all research on its experimental cancer treatment Rova-T, a drug it bought in its $5.8 billion 2016 takeover of Stemcentrx Inc.
The decision to stop work on Rova-T marks the formal end to a costly project that resulted in a $4 billion writedown by the pharmaceutical company in January.